^
Association details:
| Biomarker: | Chr t(11;14) |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Real-World Outcomes In Myeloma Patients With t(11; 14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database
Published date:
09/10/2023
Excerpt:
The most common regimens in line 2 were lenalidomide-based...Compared with non-t(11;14), those with t(11;14) had a shorter PFS in lines 1 and 2.
